You are leaving GSKpro website

The information you are about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the company or via the Product Information.

Continue

Go back

NP-AU-NA-WCNT-190017

Product menu

Choose indication Severe eosinophilic asthma

Discover Nucala, a well-tolerated targeted treatment for your patients with nasal polyps1

Find out about the safety profile of Nucala, the first anti-IL-5 for the treatment of nasal polyps1

Nucala demonstrated similar rates of on-treatment adverse events compared with placebo (82% vs. 84% respectively).2*

In the 52-week clinical trial in patients with refractory-to-treatment nasal polyps, the most frequent on-treatment adverse events for both treatment groups were:2*

  • nasopharyngitis (Nucala: 25%; placebo: 23%)
  • headache (Nucala: 18%; placebo: 22%)
  • sinusitis (Nucala: 5%; placebo: 11%)

*Aside from the three AEs listed, no other AEs were reported for more than 10% of participants in either group.2
†Transient ischaemic attack.2
‡Due to myocardial infarction during the follow-up period.2

Nucala is a well-tolerated anti-IL-5 with an adverse events profile comparable to placebo.1,2

  • In the SYNAPSE 52-week Phase III clinical study, Nucala demonstrated similar rates of on-treatment adverse events compared with placebo (82% vs. 84% respectively)2
  • The incidence of on-treatment serious adverse events was similar between the two treatment groups (6% with Nucala and 6% with placebo)2

Important product Information

Prescribing information

open

References

  1. Nucala Product Information
  2. Han JK, Bachert C, Fokkens W et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021; published online April 16.

PM-AU-MPL-WCNT-220008
Date of preparation: March 2022